Telix Pharmaceuticals (NASDAQ:TLX) Sets New 52-Week Low – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX) hit a new 52-week low on Wednesday . The company traded as low as $7.58 and last traded at $7.5830, with a volume of 12298 shares. The stock had previously closed at $7.75.

Analysts Set New Price Targets

Several brokerages have recently commented on TLX. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Monday, December 22nd. Royal Bank Of Canada assumed coverage on shares of Telix Pharmaceuticals in a research report on Monday, December 15th. They set a “hold” rating for the company. Citigroup initiated coverage on shares of Telix Pharmaceuticals in a research note on Thursday, September 18th. They issued a “buy” rating and a $22.00 price target for the company. UBS Group lowered their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, September 23rd. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Trading Down 3.4%

The company has a fifty day moving average price of $9.30 and a 200-day moving average price of $11.34.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several institutional investors have recently modified their holdings of TLX. Rhumbline Advisers increased its position in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares during the last quarter. IHT Wealth Management LLC bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth about $213,000. Blair William & Co. IL bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth about $217,000. JPMorgan Chase & Co. purchased a new position in shares of Telix Pharmaceuticals during the 3rd quarter worth about $243,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at about $297,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.